PT-141
Melanocortin receptor agonist originally developed for sexual dysfunction.
Grade
Finnrick lab signal
Lowest
Trust
Current offers across tracked vendors
Lowest price first, with Finnrick grades in the same row so cost never gets divorced from lab context.
What the Finnrick results actually show
We highlight current purity and quantity results without implying every vendor or every batch has been tested equally.
Purity distribution
No Finnrick test results are attached to this peptide yet.
No Finnrick lab results are attached to this peptide yet. We leave that state explicit rather than inferring confidence that hasn't been earned.
Historical tracking comes next
The current schema gives us a trustworthy live market snapshot. It does not yet store price snapshots over time, so the chart module stays honest about that gap.
Historical pricing
Tracking starts with snapshots
The current schema stores live prices but not historical snapshots yet, so this page shows current market comparison rather than pretending time-series data exists. Once snapshots are recorded, this module can render 30-, 90-, and 180-day trends honestly.
Editorial context beyond the price table
The goal is to keep market data inside a broader research and safety frame, not let the price table become the whole story.
PT-141 explainer
PT-141 (bremelanotide / Vyleesi) is an FDA-approved melanocortin agonist for HSDD in premenopausal women. It targets CNS receptors influencing sexual desire rather than vascular pathways.
Read the full research guide →Research information only
Peptide Daily is an informational resource only. Peptide research chemicals are not approved for human use by the FDA unless otherwise noted. Nothing on this site constitutes medical advice. Consult a qualified healthcare provider before using any peptide or research chemical.